NXTC

5.83

1.35% -0.08

Pre-mercato: 5.95 0.12 +2.06%

Nextcure Inc (NXTC)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Perché NXTC Giù? Forum Previsione

Precedente Chiudi:

$5.91

Aprire:

$5.85

Volume 24 ore:

91,109

Relative Volume:

0.04

Capitalizzazione di mercato:

$26.69M

Reddito:

Utile/perdita netta:

$-54.66M

Rapporto P/E:

-0.3057

EPS:

-19.0729

Flusso di cassa netto:

$-49.98M

1 W Prestazione:

-14.01%

1M Prestazione:

+37.50%

6M Prestazione:

-55.15%

1 anno Prestazione:

+11.69%

Intervallo 1D:

$5.60

$6.19

Intervallo di 1 settimana:

$5.60

$6.7594

Portata 52W:

$1.55

$15.74

Nextcure Inc Stock (NXTC) Company Profile

Nome

Nextcure Inc

Settore

Healthcare (1084)

Industria

Biotechnology (609)

Telefono

240-399-4900

Indirizzo

9000 VIRGINIA MANOR ROAD, SUITE 200, BELTSVILLE, MD

Dipendente

Cinguettio

@nextcureinc

Prossima data di guadagno

2026-08-06

Ultimi documenti SEC

NXTC's Discussions on Twitter

Compare NXTC vs VRTX, REGN, ARGX, MRNA, RVMD

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
NXTC Nextcure Inc	5.83	28.61M	0	-54.66M	-49.98M	-19.07
VRTX Vertex Pharmaceuticals Inc	547.29	136.93B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	814.79	85.11B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	1,047.10	64.95B	4.16B	1.29B	734.26M	19.58
MRNA Moderna Inc	149.66	53.23B	2.23B	-3.19B	-1.60B	-8.1462
RVMD Revolution Medicines Inc	215.44	45.38B	742.00K	-1.37B	-1.07B	-7.0731

Nextcure Inc Stock (NXTC) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2025-11-07	Aggiornamento	Ladenburg Thalmann	Neutral → Buy
2022-11-04	Downgrade	Ladenburg Thalmann	Buy → Neutral
2022-03-01	Iniziato	Ladenburg Thalmann	Buy
2021-03-05	Aggiornamento	Truist	Hold → Buy
2021-01-15	Downgrade	BofA Securities	Neutral → Underperform
2020-07-16	Aggiornamento	The Benchmark Company	Hold → Buy
2020-07-13	Downgrade	ROTH Capital	Buy → Neutral
2020-07-13	Downgrade	SunTrust	Buy → Hold
2020-06-01	Downgrade	BofA/Merrill	Buy → Neutral
2020-06-01	Downgrade	The Benchmark Company	Buy → Hold
2020-05-26	Iniziato	JMP Securities	Mkt Outperform
2020-03-24	Iniziato	The Benchmark Company	Buy
2020-03-02	Iniziato	ROTH Capital	Buy
2020-01-13	Iniziato	SunTrust	Buy
2019-12-05	Iniziato	Needham	Buy
2019-11-26	Iniziato	BTIG Research	Buy
2019-07-09	Iniziato	BofA/Merrill	Buy
2019-06-03	Iniziato	Morgan Stanley	Overweight
2019-06-03	Iniziato	Piper Jaffray	Overweight

Mostra tutto

Nextcure Inc Borsa (NXTC) Ultime notizie

Aug 20, 2026

NextCure (NXTC) Q2 2026 Earnings: Profit Per Share Falls Below Its Benchmark for the Current Session - vinanet.vn

Aug 20, 2026

Aug 18, 2026

NextCure (NASDAQ: NXTC) plans Avere merger backed by $820M raise - Stock Titan

Aug 18, 2026

NextCure (NXTC) Share-Price Review: Declines 11.15% to $6.85 at the Close; Current Range Read: the Near-Term Reference Band Stretches From $6.51 to $7.19 under the Current SnapshotExtension Target - vinanet.vn

Aug 18, 2026

Aug 14, 2026

Ikarian Capital discloses 9.99% NextCure (NXTC) stake including large warrant position - Stock Titan

Aug 14, 2026

NextCure (NXTC) gains 15.8% beneficial owner in ADAR1 Capital and manager - Stock Titan

Aug 14, 2026

Nextcure Stock Price Forecast. Should You Buy NXTC? - StockInvest.us

Aug 14, 2026

NextCure Inc (NASDAQ: NXTC) Stock Price, News & Analysis - Kalkine

Aug 14, 2026

NextCure (NXTC): Squadron funds and partners disclose 1.6% equity stake - Stock Titan

Aug 14, 2026

Aug 13, 2026

Affinity Asset Advisors discloses 6.4% NextCure (NXTC) stake via stock and warrants - Stock Titan

Aug 13, 2026

NextCure stock rating reiterated at Buy by H.C. Wainwright - Investing.com

Aug 13, 2026

Aug 12, 2026

Major Former Stakeholder Makes a Significant Move in NextCure Stock - TipRanks

Aug 12, 2026

Simcere Zaiming sells $184,800 of NextCure stock By Investing.com - Investing.com India

Aug 12, 2026

Adage Capital files Schedule 13G showing 7.67% NextCure (NXTC) ownership - Stock Titan

Aug 12, 2026

Simcere Zaiming sells $184,800 of NextCure stock - Investing.com

Aug 12, 2026

Simcere group (NXTC) trims NextCure stake, ends 10% beneficial ownership - Stock Titan

Aug 12, 2026

RTW Biotech's Avere to go public in US in reverse merger with NextCure - London South East

Aug 12, 2026

Aug 11, 2026

RTW Biotech Opportunities (RTWG) Supports Avere Therapeutics’ $820M Capital Raise and NextCure Reverse Merger - Kalkine Media

Aug 11, 2026

NextCure - thepharmaletter.com

Aug 11, 2026

Aug 10, 2026

NextCure (NXTC) plans reverse merger with Avere and $820M financings - Stock Titan

Aug 10, 2026

Xcellon Acquires 40,000 Sq ft Maryland Facility from NextCure to Deliver a cGMP-Ready CRDMO for ADCs - BioBuzz

Aug 10, 2026

Xcellon Biologics Acquires GMP Manufacturing Facility from NextCure, Becoming an End-to-End CRDMO for Next-Generation Bioconjugates and Complex Biologics - The Manila Times

Aug 10, 2026

Avere Therapeutics Announces $500 Million Private Placement to Support Development of Once-Weekly Oral IL-23 Therapy AVR-001 - Nasdaq

Aug 10, 2026

Aug 09, 2026